| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |